Skip to main content

Articles Tagged With:

  • Clinical Briefs in Primary Care

    Oral Prednisolone for Acute Gout; Adding Aliskiren to Losartan for Diabetic Nephropathy; Early Aggressive Therapy in Type 2 Diabetes Pays Off; Sublingual Immunotherapy; Methylnaltrexone for Opioid-Induced Constipation; Prucalopride for Severe Constipation
  • Full August 2008 Issue in PDF

  • Full July 1, 2008 Issue in PDF

  • Airport to staircase, Medtronic steps up big at HRS sessions

    SAN FRANCISCO Big medical companies usually have big footprints at medical conferences, and Medtronic stomped around with one of the very largest CD&D has ever seen at this year's scientific sessions of the Heart Rhythm Society (HRS; Washington).
  • Medtronic's left-heart CRT lead is okayed

    Medtronic (Minneapolis) in mid-June received FDA approval of its Attain StarFix OTW (over-the-wire) lead. The company said it's the first active fixation left-heart lead for cardiac resynchronization therapy (CRT) and that the lead has demonstrated a 0% chronic (meaning more than one day post-implant) dislodgement rate.
  • International report: European cardiologists pushing good habits

    It takes a team to change the high-risk lifestyle habits of a single individual according to a large-scale study conducted by the European Society of Cardiology (ESC; Sophia Antipolis, France) published in the June 14 issue of The Lancet.
  • Acquisitions

    Applera; Celera; Berkeley HeartLab; Abbott Laboratories; Applied Biosystems; Invitrogen; Escalon Medical; Drew Scientific; JAS Diagnostics; Kardia Health Systems; Freeland Systems; Pediatrix Medical Group
  • Business developments: Boston Sci sells most of private portfolio

    In a move that could help offset its $458 million 4Q07 Gudiant-related losses, Boston Scientific (Natick, Massachusetts) reported last month that it had signed a definitive agreement to sell its investments in a portfolio of companies, subject to certain closing and other conditions, to Saints Capital (San Francisco), a secondary direct-investment firm.
  • Agreements

    Cook Medical; HealthTrust Purchasing Group; Freescale Semiconductor; Monebo Technologies; HemCon Medical Technologies; SanguiBioTech; LifeScan; ResMed; Johnson & Johnson; IDev Technologies; YMed; Positron; Disease Management; NuView Radiopharmaceuticals
  • Market updates: JAMA study: DES benefits outweigh risks

    After more than two years of clinical data linking drug-eluting stents (DES) with an increased risk of stent thrombosis compared to their bare-metal cousins, a study in the Journal of the American Medical Association (JAMA) may shed some positive light on the DES space.